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Impaired functional activity of T regulatory (Treg) cells results in an increased 
susceptibility to autoimmune diseases and has been reported in allergic 
patients. The deficiency for Treg-mediated regulation of the pro-allergic 
effector T cells results in uncontrolled immune reaction against otherwise 
innocuous antigens. This lack of regulation underlines the critical role of Treg 
cells in preserving immune homeostasis by maintaining tolerance to self and 
innocuous antigens.  
 
Treg cells require the transcription factor FOXP3 for both their development 
and function. Mutations in the foxp3 gene impair the development of Treg 
cells and cause a condition known as immunodysregulation, 
polyendocrinopathy and enteropathy, X-linked syndrome (IPEX). This illness 
is characterized by severe autoimmune phenomena including autoimmune 
enteropathy, dermatitis, thyroiditis, and type 1 diabetes. Given the importance 
of FOXP3 in the generation and maintenance of Treg cells, understanding the 
molecular mechanisms regulating its expression is of great interest and 
provides new perspectives to control autoimmune diseases and allergies. 
 
Although TGF-β signalling allows FOXP3 expression in naïve CD4+ T cells 
upon activation, little is known about the molecular mechanisms regulating 
foxp3 gene expression. This thesis describes a mechanism by which the 
STAT1-activating cytokines, IL-27 and IFN-γ, amplify TGF-β-induced FOXP3 
expression. We identified STAT1-binding elements within the proximal part of 
the FOXP3 promoter, which we previously hypothesized to function as a key 
regulatory unit. Direct binding of STAT1 to FOXP3 promoter increases its 
transactivation by modulating chromatin availability, which increases FOXP3 
expression. We reveal that the Th1 cytokines IFN-γ and IL-27 are potentiating 
the induction of TGF-β-induced Treg cells. This study provides a new 
understanding of molecular mechanism regulating FOXP3 expression and is 
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of considerable significance for the elaboration of therapies aiming to restore 






Eine verminderte Funktion von regulatorischen T (Treg) Zellen führt zu einem 
erhöhten Auftreten von Autoimmunerkrankungen und ist darüber hinaus bei 
allergischen Patienten bekannt. Hier bedingt eine fehlende Treg-vermittelte 
Suppression der pro-allergischen Effektor-T Zellen eine unkontrollierte 
Immunreaktion gegen normalerweise harmlose Antigene. Diese mangelnde 
Regulierung der Immunantwort unterstreicht die entscheidende Rolle von 
Treg Zellen, Toleranz zu körpereigenen und harmlosen Antigenen 
aufrechtzuhalten und dadurch das Immunsystem im Gleichgewicht zu halten. 
Treg Zellen benötigen den Transkriptionsfaktor FOXP3 sowohl für ihre 
Entwicklung als auch für ihre Funktion. Mutationen im foxp3 Gen führen zu 
einer unvollständigen Entwicklung der Treg Zellen und verursachen das 
sogenannte X-chromosomal vererbte Syndrom mit Immundysregulation, 
Polyendokrinopathie und Enteropathie (IPEX). Diese Krankheit äussert sich 
durch schwere autoimmune Erkrankungen wie autoimmuner Enteropathie, 
Hautentzündungen, Thyroiditis und Diabetes Typ 1. In Anbetracht der 
entscheidenden Rolle von FOXP3 in der Generierung und Aufrechterhaltung 
von Treg Zellen ist das Verständnis der molekularen Mechanismen, welche 
die FOXP3-Expression regeln, von großem Interesse und stellt neue 
Perspektiven dar, um Autoimmunerkrankungen und Allergien zu kontrollieren. 
Obwohl TGF-β die FOXP3-Expression in naiven CD4 T Zellen nach deren 
Aktivierung induziert, ist wenig über die molekularen Mechanismen bekannt, 
welche die foxp3-Genexpression regeln. Die vorliegende Dissertation 
beschreibt einen Mechanismus, durch den die STAT1-aktivierenden Zytokine 
IL-27 und IFN-γ die TGF-β-induzierte Expression von FOXP3 verstärken. Wir 
identifizierten STAT1-bindende Elemente innerhalb des proximalen Teils des 
FOXP3 Promotors, welcher gemäß unserer vorausgehenden Hypothese eine 
Schlüsselrolle in der Regulation spielt. Die direkte Bindung von STAT1 an den 
FOXP3 Promotor führt zu einer Veränderung der Chromatin-Struktur, was die 
FOXP3-Expression verstärkt. Wir zeigen, dass die Th1-spezifischen Zytokine 
IFN-γ und IL-27 die Induktion von TGF-β induzierten Treg Zellen 
Zusammenfassung 
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vervielfachen. Diese Studie führt zu einem neuen Verständnis der 
molekularen Mechanismen, welche die FOXP3-Expression regeln und ist 
damit für die Entwicklung von Therapien mit dem Ziel, Toleranz durch 
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1.1 The immune system 
The human organism continuously encounters a diversity of potentially 
harmful pathogens. In response to this constant threat, the human immune 
system has elaborated a sophisticated anti-pathogen organization involving 2 
interacting parts; the innate and the adaptive immunity (Figure 1). Via physical 
and chemical barriers, the innate immune system represents the first line of 
host response to pathogen invasion. The cells of the innate immune system 
interact with pattern recognition receptors and are responsible for the 
recruitment of immune cells to sites of infection and inflammation. They also 
activate the complement cascade to identify bacteria and promote clearance 
of dead cells or antibody complexes. By secreting cytokines or chemokines, 
they activate the adaptive immune system through a process known as 
antigen presentation. The specific functions of the adaptive immune system 
are mediated via responder cells, the T and B lymphocytes. Antigen-mediated 
triggering of T and B cell receptors initiates specific cell-mediated and humoral 
immune responses characterised by cytokines or antibody production 
respectively. The rearrangement of the variable, diversity, and junction gene 
segments of their receptors generates a repertoire, which is sufficiently 
diverse to recognize the antigenic component of potential pathogen or toxin 
[1].  
 
Both innate and adaptive immunity depend on the ability of the immune 
system to distinguish between harmless self (e.g. components of an 
organism's body) and non-self pathogenic molecules (e.g. foreign 
substances). In the healthy individual, the immune system is delicately 
balanced between self-antigen-driven tolerance and pathogen-driven 
immunity. A disturbance of this equilibrium results in pathological conditions 
and severe diseases. The lack of an immune response provokes recurring 
and life-threatening infections. Immunodeficiency can be the result of a 
genetic disease, such as severe combined immunodeficiency, or be produced 
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by pharmaceuticals or infections, such as the acquired immune deficiency 
syndrome (AIDS) caused by human immunodeficiency virus. An inappropriate 
response against self leads to autoimmunity. Common autoimmune diseases 
include rheumatoid arthritis, diabetes mellitus type 1 and lupus erythematous. 
An excessive response is characterized by an immune reaction against an 




Figure 1: The interactions between innate and adaptive immune system 
 
The cells of the innate immune system secrete cytokines and chemokines that activate 
cells from the adaptive immune system. NK: Natural Killer cells, NKT: Natural Killer T 







The immune system’s organs are called lymphoid organs and they contain a 
high number of lymphocytes. Interactions between immune and non-immune 
cells are critical for lymphocyte development and initiation of the immune 
response. The primary lymphoid organs are the sites for the lymphopoiesis, 
the cellular differentiation of lymphocytes. Both B and T cells are generated in 
the bone marrow, but only T cell precursors leave the bone marrow for the 
thymus, which provides the suitable environment for T cell ontogeny. B cell 
development occurs in the bone marrow. The peripheral, secondary lymphatic 
tissues are responsible for T and B cells’ commitment into specialised 
subtypes. Those organs comprise spleen, tonsils, lymph vessels, lymph 
nodes, adenoids, and skin (Figure 2).  




1.2 Decision making during an immune response 
Dendritic cells have a pivotal role in the interrelationship between innate and 
adaptive immunity [2]. Upon encountering a pathogen in peripheral tissues, 
the immature dendritic cells (iDC) undergo a maturation step allowing them to 
increase their costimulatory activity, antigen processing, and major 
histocompatibility complex (MHC) molecule expression while migrating to the 
lymph nodes. [2]. Secondary lymphoid organs are the key sites for the 
antigen-driven lymphocyte differentiation. This process requires recognition of 
peptide antigens presented by MHC molecules and costimulatory molecules 
expressed on the same antigen presenting cells (APC). For the activation of 
naïve T lymphocyte to successfully induce an immune response, 
costimulatory signals are necessary. First, the T cells are activated by the 
engagement of their surface receptor (TCR), which ensures antigen specificity 
and MHC restriction of the response. Synergistic signalling by costimulatory 
molecules is also necessary to sustain and integrate TCR signalling to 
stimulate optimal T cell proliferation and differentiation [3]. Cytokine 
production by pathogen-activated immune cells is also needed and direct the 
type of immune response by orchestrating lineage specific transcription factor 
and cytokine expression. The differentiation of CD4+ naïve T cells into clonally 
restricted effector T cells is characterized by the acquisition of a T helper (Th) 
subset-specific cytokine profile. Figure 3 to 5 depict the events occurring 
during the naïve CD4+ T cells differentiation into Th1, Th2 or Th17 cells.  
1.2.1 Th1 cells 
Type 1-associated pathogens include viruses and bacteria. In response to 
those pathogens, activated APCs produce IL-12, which was identified as the 
main Th1-inducing factor. Expressing low levels of IL-12 receptor β2 (IL-
12Rβ2) at the resting state, naïve CD4+ T cells require TCR, IL-27 or IFN-γ 
stimulation to increase their IL-12 responsiveness. APC-produced IL-12 also 
favours the recruitment of IFN-γ producing NK cells. Both IL-27 and IFN-γ are 
STAT1-activating cytokines and their receptors are expressed on naïve cells 
[4-6]. STAT1 signalling induces the Th1-specific T box transcription factor (T-
Introduction 
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bet), which is the master regulator of Th1 differentiation [7,8] and interferon 
regulatory factor 1 (IRF1) transcription factor [9]. In addition to the negative 
regulation of the Th2 specific transcription factor GATA-binding protein 3 
(GATA-3) [10], T-bet potentiates expression of the ifnγ gene and up-regulates 
the IL-12Rβ2, whereas IRF1 directly regulates the IL-12Rβ1 [9]. This enables 
the formation of the IL-12R complex, which is coupled to the Jak2 and Tyk2 
kinases and the transcription factor STAT4. Activation of the IL-12R complex 
further stimulates IFN-γ production and induces expression of IL-18Rα, 
thereby conferring IL-18’s responsiveness to mature Th1 cells. IL-18 serves 
as a cofactor for IL-12-induced Th1 development and enhances IFN-γ 
production from effector Th1 cells. Th1 cells express IFN-γ and lymphotoxin-α 
(LT-α) and mobilize the cellular arm of the immune system. Excessive Th1 
responses are associated with various autoimmune and inflammatory 







Figure 3: Overview of Th1 cell differentiation 
 
The type 1-associated pathogens induce IL-12, IL-27 and IFN-γ production from innate 
immune cells (e.g. mDC and NK cells). Those cytokines activate STAT1, STAT4, T-bet 
and IRF-1, which leads to the establishment of Th1 phenotype, which includes up-
regulation of IL-18R and IFN-γ, IL-2 and LT-α production. IL-18 and IFN-γ stimulation 
further  participates in induction of IFN-γ-producing cells.  
Introduction 
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1.2.2 Th2 cells 
Helminths are characterized as type 2-associated pathogens.  However, it is 
unclear how they instruct DCs to produce Th2-inducing factors. In vitro studies 
identified IL-4 as the main Th2-driving cytokine [11], but its contribution in vivo 
is unclear. The cellular source of IL-4 in vivo is the subject of considerable 
debate, but basophils, eosinophils, mast cells and NKT cells, are an important 
source of IL-4 and have been proposed to be important for Th2 cell 
differentiation [12,13]. Recently, basophils have been shown to be recruited 
into draining lymph nodes when stimulated by allergens with enzymatic 
activity and to produce Th2 promoting factors [14]. The thymic stromal 
lymphopoietin (TSLP) has also been linked to Th2 differentiation, but whether 
it acts on DCs or T cells, and whether its involvement is IL-4-dependent or 
independent is controversial [15]. Th2 differentiation is initiated by signals that 
originate from the TCR and IL-4 receptors and act cooperatively to up-regulate 
low-level expression of GATA-3, the master regulator of Th2 differentiation, in 
a STAT6-dependent manner [16-18]. GATA-3 auto-activates its own 
expression and drives epigenetic changes that enable expression of the Th2 
cytokine cluster (il4, il5, and il13 genes), while suppressing factors critical to 
the Th1 pathway, such as STAT4 and the IL-12Rβ2 chain [19-21]. Thus, early 
IL-4 signalling rapidly initiates positive and negative feedback loops that serve 
to reinforce early commitment to Th2 development, while extinguishing Th1 
development. Th2 cells secrete cytokines, including IL-4, IL-13, and IL-5, 
which are essential for optimal antibody production and elimination of 
extracellular pathogens. Deregulated production of Th2-derived cytokines, 
such as IL-4, IL-5 and IL-13, results in immunopathology and is critical for 





















Figure 4: Overview of Th2 cell differentiation 
The type 2-associated pathogens induce the recruitment of IL-4-producing cells (e.g. 
Eosinophils, Basophils, Mast cells and NKT cells). TSLP is linked to Th2 differentiation, 
but whether it acts on DC or T cells, and whether its involvement is IL-4-dependent or 
independent is controversial. IL-4 activates STAT6, which induces GATA-3 expression 
and  leads to the establishment of Th2 phenotype. Th2 cells produce many cytokines and 




1.2.3 Th17 cells 
Th17 cells are specialized for enhanced host protection against extracellular 
bacteria and some fungi. Recently discovered, the requirement for their 
differentiation is not totally elucidated. Although the differentiation of human 
and murine Th17 cells may not be identical, there seems to be a consensus 
that when IL-6 is produced in concert with TGF-β, they act together on naïve 
CD4+ T cells, via STAT3, to induce the expression of the retinoic orphan 
receptor (ROR)-γt also designated as RORC2. This Th17 cell specific 
transcription factor up-regulates the expression of IL-23R and allow the cells 
to become competent for IL-17A, IL-17F and IL-22 production [24,25]. Human 
Th17 cells may also produce IL-26 [26], whereas murine Th17 cells have 
been shown to produce TNF-α and IL-6 [27]. Expression of the IL-23R [26,28] 
and the chemokine receptor CCR6 [28-32] additionally define this subset. IL-
17 is present in multiple chronic inflammatory responses including 
angiogenesis, recruitment of inflammatory cells, and induction of pro-
inflammatory mediators by endothelial and epithelial tissues [33]. Many 
immune responses that were thought to be Th1 immune responses are now 
described as Th17 cell-mediated responses. Experimental autoimmune 
encephalomyelitis (EAE) is an example. In fact, IL-12 and IFN-γ were found to 
suppress IL-17 production, and the lack of this suppression in IL-12- or IFN-γ-
deficient mice contributes to EAE exacerbation [27]. Furthermore, passive 
transfer of IL-17-producing activated memory CD4+ T cells induced EAE, 







Figure 5: Overview of Th17 cell differentiation 
The type 17-associated pathogens induce the production of IL-6 and TGF-β by DC. Via the 
activation of STAT3, ROR-yt (that is also named RORC2) is activated and participates in the 
establishment of Th17 phenotype. The cells up-regulate CCR6 and IL-23R and become 




1.3 Concept of Immune Tolerance  
The mammalian immune system possesses the remarkable capacity to 
endure continued subjection to self-antigens. Imposition and regulation of this 
self-tolerance within the T cell repertoire is exerted at 2 levels. Central 
tolerance refers to the deletion of developing autoreactive T cells that bind 
with high-affinity to intrathymic self-antigens [34,35]. Despite this stringent 
selection, autoreactive T cells can evade the thymus. Peripheral regulatory 
mechanisms are then required for the prevention of autoimmunity [36-39]. 
This requirement to prevent excessive activity led to rapid acceptance of a T 
suppressor or Treg cell population. Treg cells may suppress the activation of 
those self-reactive T cells that escape selection [39,40]. 
 
The importance of central and peripheral tolerance to immune health has 
been shown in recent years with the understanding of the molecular basis of 2 
inherited autoimmune syndromes. In both cases, the affected molecules are 
transcriptional regulators: the autoimmune regulator (AIRE) and the forkhead 
box P3 (FOXP3). Mutations in the aire gene lead to defective clonal deletion 
of T cells and to the multi-organ syndrome known as autoimmune 
polyendocrinopathy-candidiasis-ectodermal-dystrophy syndrome (APECED) 
[41]. Mutations in the foxp3 gene impair the development of Treg cells and 
cause the syndrome known as immunodysregulation, polyendocrinopathy and 
enteropathy, X-linked syndrome (IPEX) [42]. The association between 
autoimmune diseases and mutations at particular genetic loci suggests a 
causal relationship. 
 
1.3.1 Central Tolerance 
The random generation of receptor specificities during T cell differentiation 
increases the potential to respond to self-proteins, which would result in 
autoimmune tissue damage. To bypass this problem, one approach is to test 
T cells for self-reactivity during their maturation in the thymus and to delete 
those posing the greatest menace. Thus, central tolerance represents the 
Introduction 
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mechanism by which newly developing T cells are selected for lack of high 
reactivity to self (Figure 6). Thymocyte progenitors mature in thymus from 
double negative (DN) 1 to DN4 stage. The random production of TCR during 
their differentiation towards the double positive (DP) stage generates many 
unsuccessful TCR.  
 
Positive selection is a crucial step that enriches for MHC restricted T cell 
progenitors by allowing only cells that express a TCR that can interact with 
self-peptide-MHC complexes to further differentiate. Immature DP progenitors 
can be positively selected when they encounter an appropriate self-peptide-
MHC complex on cortical thymic epithelial cells (cTECs) [43].  
 
Negative selection is necessary to eliminate potentially autoreactive T cells 
generated during positive selection. Positively selected DP thymocytes 
migrate towards the medulla and interact with medullary thymic epithelial cells 
(mTECs) that express costimulatory molecules and peripheral tissue-specific 
antigens (TSAs) under the control of the transcriptional regulator AIRE [44, 
45]. DCs are also present in the medulla. They express costimulatory 
molecules, such as CD40, CD80, and can cross-present TSAs that are 
produced by mTECs to developing T cells and thereby induce clonal deletion.  
 
The main mechanism of negative selection is clonal deletion, but receptor 
editing and anergy have also been described, whereas these are thought to 
have a minor role. These 3 processes impair or eliminate high-affinity self-
reactive thymocytes. All are thought to be induced by high affinity self-peptide-
MHC interactions with TCR in the thymus [46]. It was reported that a 
mechanism selecting for high-affinity self-reactive cells results in 









  1.3.2 Peripheral Tolerance 
Although central-tolerance mechanisms are efficient, they are unlikely to 
eliminate all self-reactive lymphocytes. Low affinity TCR for self-antigens have 
been found in healthy individual in the periphery [50-52], which is consistent 
with the predominant deletion of high-affinity cells in the thymus. Peripheral 
tolerance mechanisms have been invoked to explain the absence of auto-
reactivity toward tissue-restricted self-constituents. Peripheral tolerance can 
act at several levels using mechanisms acting either directly on the self-
reactive T cell, named T cell intrinsic, or indirectly via additional cells, 
Figure 6: Central and Peripheral tolerance mechanisms. 
 
During the development of T lymphocytes in the thymus, central tolerance mechanisms 
eliminate most of the self reactive T cells. Peripheral Tolerance mechanisms in the 
peripheric lymphoid organs are necessary to complete this elimination. 
Introduction 
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designated T cell extrinsic. T cell intrinsic mechanisms comprise ignorance, 
anergy, phenotypic skewing and apoptosis, whereas T cell extrinsic 
mechanisms include tolerogenic DC and Treg cells (Figure 6). 
 
1.3.2.1 T cell intrinsic mechanisms 
Four T cell intrinsic mechanisms are known to play a role in immune 
tolerance: ignorance, anergy, phenotype skewing and apoptosis. The concept 
of ignorance involves anatomic separation. By hiding self antigens behind a 
tissue barrier impermeable for circulating immune cells, self-reactive T cells 
might never encounter the self-protein they recognize, and therefore exist in a 
state of ignorance. Anergy was first described as the result of TCR ligation in 
the absence of costimulation [53,54]. However, later studies showed that 
anergy possibly involves interaction with inhibitory molecules, which are 
induced after encountering self-proteins. The T cell inhibitory molecules 
consist of the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) [55] and 
the programmed death-1 (PD-1) [56,57]. Phenotype skewing refers to a full 
activation of the T cells interacting with self-protein. In this case, self-reactive 
T cells become activated but fail to induce autoimmune tissue damage 
because of impaired lymphocyte trafficking. Finally, self-reactive T cells might 
undergo apoptosis following contact with self-protein by activation-induced cell 
death (AICD) involving up-regulation of T cell Fas ligand and subsequent 
signalling through the death receptor Fas [58]. 
 
1.3.2.2 T cell extrinsic mechanisms 
DCs have emerged as the key APCs involved in process initiating immune 
responses and inducing T cell tolerance. Whether any immature DC can 
perform a tolerogenic function, or whether this task is mediated by a distinct 
lineage of DCs is unknown. Following pathogen exposure, DCs undergo a 
maturation process, which modifies their antigen-processing capacity and 
their surface phenotype [1]. Their capacity to activate T cells is gained by up-
regulating costimulatory molecules. Consequently, the ability of DCs to initiate 
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immune responses would depend on encountering a pathogen-associated 
molecule [59]. DCs constantly take up self-proteins and present them to self-
reactive T cells. In the absence of a pathogen trigger, the low expression of 
costimulatory molecules by those immature DCs or by a distinct subset of 
'tolerogenic' DCs, leads to T cell tolerance rather than activation [38]. It is 
possible that immature or 'tolerogenic' DCs maintain T cell tolerance indirectly 




1.3.3 T regulatory cells 
T cells were shown to possess, in addition to their effector and positive co-
operative functions, a role in depressing immune responses [61-71]. These 
previously named suppressor T cells are now termed Treg cells. They can 
mediate their suppressive mechanisms via cell-contact-dependent 
mechanisms [72], inhibitory cytokine production (IL-10 or TGF-β) [73,74] or by 
consumption of T cell growth factors [75]. In contrast to effector cells that can 
be characterized by their unique cytokine profile Treg cells do not produce 
specific cytokines. Even though IL-10 and TGF-β have often been identified 
as Treg cytokines, they are not Treg cell-exclusive. Recently, IL-35 has been 
shown to be constitutively and exclusively produced by mouse Treg cells [76]. 
IL-35 is an heterodimeric cytokine consisting of the Epstein-Barr virus induced 
gene 3 (EBI3) and the IL-12-p35 subunit. Treg from EBI3-/- and p35-/- mice 
had reduced regulatory activity both in vitro and in vivo, which indicated that in 
mice, the EBI3–p35 complex (IL-35) is required for the suppressive activity of 
regulatory T cells.  
 
1.3.3.1 Naturally occurring Treg cells 
Naturally occurring CD4+CD25+Treg cells comprise 3%-10% of peripheral 
CD4+ T cells and are the major population of suppressing T cells maintaining 
peripheral immune tolerance to self antigens [77]. The natural Treg cells 
originate from the thymus [49,78] and require the expression of the FOXP3 
transcription factor for their development and function [79,80]. How the 
differentiation of the natural Treg is regulated is not fully understood, but it 
requires a high affinity self reactive TCR [49]. It was postulated that TSLP 
instructed DCs positively select Treg cells exhibiting medium to high self-
reactive affinity within the medulla of the thymus [81]. CD28-costimulation 
directly signals DP thymocytes to express FOXP3, as well as glucocorticoid-
induced TNF receptor family related receptor (GITR) and CTLA-4, which 
initiate the Treg cell differentiation program. [82]. Mature Treg can be 
identified by their constitutive expression of CD25, CTLA-4, and GITR [83-85]. 
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Natural Treg cells that migrate in the periphery keep their phenotype and 









Figure 7: Induction of Treg cells in the thymus and in the periphery 
 
Natural Treg cell differentiation occurs in the thymus whereas iTreg cells differentiation 
takes place in the periphery. Natural Treg cells originate from high affinity self-reactive 
TCR bearing SP thymocytes activated by TLSP instructed DC, CD28 or γ chain cytokines. 
They express high levels of CD25, CTLA-4 and GITR and control autoimmunity. Adaptive 
or iTreg cells originate from CD25- precursor or naïve CD4+ T cells. Induced by tolerogenic 
or immature DCs, low dose of antigen, γ chain cytokines or TGF-β, they expressed 
variable levels of CD25 and they control inflammation.  
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1.3.3.2 Inducible or adaptive  Treg cells 
In parallel to the natural Treg, other subsets of CD4+ Treg cells have been 
described to successfully control immune responses not only to self-antigens 
but also to a wide variety of non self-antigens (microbial, tumoral, and 
transplantation antigens). These CD4+FOXP3+ Treg cells, termed adaptive or 
inducible (iTreg), are not present in the thymus and can be generated in 
peripheral lymphoid tissues from peripheral precursors that are CD4+CD25- or 
from naive CD4+FOXP3- progenitors. Two major factors appear to be involved 
in the generation of functional FOXP3+ Treg in the periphery; the mode of 
antigen presentation, and the presence of specialized immunoregulatory 
cytokines. Immature or tolerogenic DCs have also been associated with the 
generation of Treg cells in the periphery. Low dose of antigen presented by 
DC seem to be important for adaptive Treg’s generation. The role for TGF-β in 
the induction of Treg cells is now well accepted. TGF-β can induce naive 
human CD4+ T cells to develop powerful contact-dependent suppressor 
activity that is mediated by TGF-β or IL-10 [86]. The unique cytokine 
dependence is one of the main features that differentiate adaptive from 
natural Treg cells. However, the expression of the transcription factor FOXP3 




1.4 FOXP3: the master regulator of Treg cells  
The characterization of the IPEX syndrome and the mapping of the syndrome 
to the X chromosome greatly improved our understanding of the function of 
FOXP3.  IPEX is a rare disorder caused by mutations in the Foxp3 gene that 
result in the defective development of Treg cells and leads to severe 
autoimmune disease including autoimmune enteropathy, dermatitis, 
thyroiditis, and type 1 diabetes, frequently resulting in death within the first 2 
years of life [87]. FOXP3 belongs to the forkhead (FKH) factor family, 
containing 3 functional domains: a highly conserved C-terminal winged-
helix/forkhead deoxyribonucleic acid (DNA)-binding domain, a C2H2 zinc 
finger, and a leucine zipper [87]. The N-terminal domain of FOXP3 is unique 
to the FOXP subfamily, and it is critical for transcriptional repression [87]. With 
the exception of the zinc-finger motif, mutations have been found in each of 
the functional domains of the foxp3 gene in individuals affected by IPEX, 
which indicates that each of these regions are important for proper FOXP3 
function [88-90]. Mutations in the FKH domain of FOXP3 have been shown to 
affect its ability to bind DNA, whereas 2 separate mutations in the leucine-
zipper-like motif have been found to affect the homo- and heterodimerization 
of FOXP3 [91,92]. Many of the FOXP3 mutations observed in IPEX syndrome 
are missense mutations in the FOXP3 FKH domain, but mutations have been 
found across the length of the gene. Mutations in the FKH domain ablate the 
ability of FOXP3 to inhibit transcription of a reporter construct [91]. 
Interestingly, some IPEX patients were shown to have single codon mutations 
in the leucine zipper domain of FOXP3 resulting in a failure to homodimerize 
and in reduced ability to repress transcription [93,94]. These data strongly 
suggest that the leucine zipper domain of FOXP3 is critical for proper function. 
Additional mutations in the amino terminal domain have been identified as 
critical for FOXP3 function. 
Introduction 
 20 
1.4.1 The function of FOXP3 
It is now well documented that FOXP3 is the key transcription factor for the 
development and function of Treg cells. [80]. Two recent studies used 
chromatin immunoprecipitation-on-chip (ChIP-on-chip) technology to identify 
the targets of FOXP3 and showed that FOXP3 could function both as a 
transcriptional activator and a transcriptional repressor. Comparison of 
primary CD4+Foxp3+ with CD4+Foxp3- mouse T cells outlined approximately 
700 genes that are regulated by Foxp3 [95]. The use of a T cell hybridoma 
that either did or did not express an introduced foxp3 gene underlined that 
about 1,100 genes are Foxp3 regulated [96]. Both studies found that most of 
the Foxp3-target genes identified by the ChIP-on-chip analyses were 
differentially regulated in naturally occurring Treg cells. A more targeted ChIP-
on-chip study using human Treg cells showed that CD127 (which encodes the 
IL-7 receptor α-chain) is a FOXP3-target gene and is negatively regulated by 
FOXP3 [97]. 
 
Although the mechanisms by which FOXP3 produces Treg-cell-mediated 
suppression of various immune cells are largely unknown, it is clear that the 
function of FOXP3 is dependent on its binding partners, including several key 
transcription factors and various corepressors and/or coactivators in 
regulatory T cells [98]. FOXP3 can be an acetylated protein [99] or an 
oligomeric component of a large molecular complex [100,101]. One 
mechanism of FOXP3-mediated transcriptional repression involves direct 
contact with the nuclear factor of activated T cells (NFAT) and its subsequent 
inhibition. FOXP3 and NFAT can bind cooperatively to a binding site on the IL-
2 promoter and inhibit its expression [102]. The ability of FOXP3 to inhibit 
transcription was abolished by mutation of the residues in its FKH domain that 
are predicted to interact with NFAT. Furthermore, FOXP3 actively represses 
transcription at the chromatin level by recruiting corepressors such as the 
histone acetyltransferase (HAT), Tat interacting protein 60kDa (TIP60) ,and 
histone deacetylases (HDAC) 7 that favour a restrictive chromatin 
conformation [98,99]. In addition to its interaction with NFATc2 [102,103], 
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FOXP3 has been shown to cofractionate with other transcriptional factors in a 
low molecular weight complex. [100]. So FOXP3 can interact with acute 
myeloid leukaemia 1/ runt-related transcription factor 1 (AML1/RUNX1), [104], 
FOXP1 [101,105], ROR-α [87] or ROR-γt [106]. Other FOXP3-associated 
chromatin remodelling factors, including brahma-related gene 1 (BRG1), 70 
/80 kDa subunit of Ku antigen (Ku70/Ku80) and methyl-CpG binding domain 
protein 3 (MBD3), cofractionate with nuclear FOXP3 in larger molecular 
weight complexes [100]. FOXP3-associated chromatin remodelling factors 
and enzymatic subunits may be affected by diverse signals and may modify 
FOXP3’s target and function.  
 
Several recent papers have addressed the precise role of FOXP3 in Treg cell 
development and function in the thymus and in the periphery. The use of male 
mice carrying the Foxp3-green fluorescent protein (GFP) knock-in allele, 
resulting in a fluorescent non-functional Foxp3 protein, demonstrated that 
Foxp3 was necessary for induction and maintenance of Treg cell phenotype 
and function. While retaining many of the cell-surface markers of natural Treg 
cells, the Foxp3-knockout T cells from those mice lacked suppressor function. 
However, they regained the ability to proliferate and produce cytokines when 
stimulated [107,108]. This indicates that Foxp3 is required for the suppressive 
functions of Treg cells, as well as for their anergic state, but other factors have 
important roles in Treg cell development. The complete lack of FOXP3 during 
neonatal development results in fatal autoimmunity. However, a reduction in 
the level of FOXP3 also leads to the same phenotype [109,110]. This 
underlines that not only the presence of FOXP3 is important for Treg cell 
function, but its expression level is also crucial [111,112]. 
1.4.2 The regulation of FOXP3 
Even though FOXP3 is required for the development and function of Treg 
cells both in the thymus and in the periphery [79,80], relatively little is known 
about the molecular mechanisms regulating foxp3 gene expression. A variety 
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of signals have been described to positively influence FOXP3 expression 
(Figure 8).  
1.4.2.1 The role of TGF-β   
TGF-β is a pleiotropic cytokine, which is implicated in the regulation of 
immune responses [113]. Ablation of either TGF-β or its receptor results in 
excessive T cell responses and severe autoimmunity [114-116]. TGF-β 
induces the conversion of naive CD4+ T cells into FOXP3+ Treg cells in vitro 
and is important for the maintenance of Treg cells in vivo [114,117-119]. The 
TGF-β-converted CD4+ T cells exhibited cell-contact-dependent suppressor 
activity in vitro when cocultured with normal CD4+ T cells [117,118]. However, 
until recently, no specific mechanism had been proposed to explain the TGF-
β-induced FOXP3 expression. A positive autoregulatory loop was postulated, 
in which Smad7, a transcription factor that is normally induced by TGF-β and 
limits TGF-β signalling, is down-regulated by FOXP3 [118]. This down-
regulation of Smad7 renders CD25- T cells highly susceptible to the further 
inductive effects of TGF-β signalling via Smad3 and Smad4. Recently, Smad3 
and NFAT have been described to cooperate to induce FOXP3 expression by 
binding and acting on its enhancer [120]. The ubiquitination of the 
transcription factor TGF-β-inducible early gene 1 (TIEG1) by Itch also 
increase the transcriptional activation of the FOXP3 promoter [121]. Together, 
these recent findings propose a molecular mechanism of FOXP3 induction by 
TGF-β, but further studies are needed to complete our understanding of the 
regulation of FOXP3.   
1.4.2.2 The role of the T cell receptor 
TCR triggering is a main feature of naïve cell differentiation and is necessary 
for the induction of FOXP3. Studies of FOXP3 regulation have revealed a 
proximal 5’ regulatory region of the FOXP3 promoter containing NFAT and 
AP-1 binding sites and were reported to contribute to TCR-mediated 
regulation of the foxp3 gene [122]. Binding of transcription factors stimulating 
protein-1 (Sp-1), NFAT, activator protein 1 (AP-1) to the FOXP3 promoter 
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have also been reported and are important for the regulation of the gene 
[123]. A potent new TCR response element in the foxp3 gene that 
demonstrate DNA methylation-dependent control of foxp3 gene expression, 
have also  been identified [124]. 
 
Figure 8: Intracellular pathways controlling Treg cells differentiation 
 
TGF-β, IL-2R and TCR/CD28 act in concert on foxp3, cd25 and il2 genes to control Treg cell 
differentiation. 
 
1.4.2.3 The role of IL-2 
Early paradigm proposed a central role of IL-2 in protective immune response 
by supporting effector T cells growth and acting as a mitogenic cytokine. 
However, much data support an essential role in immune tolerance. IL-2 acts 
by binding to the high affinity IL-2 receptor consisting of 3 subunits: IL-2Rα 
(CD25), IL-2Rβ (CD122), and the common gamma chain or γc (CD132). CD25 
expression by Treg cells is influenced by TCR activation and IL-2 up-
regulation. It was shown that TCR activation and TGF-β signalling also 
regulate CD25 expression and that the constitutive expression of CD25 by 
Treg cells might partly be due through their production of TGF-β [125]. The 
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serious lymphoproliferative and autoimmune disorder observed in IL-2R α or β 
deficient mice is due to the inability to produce Treg cells [126-129]. In 
addition to its contribution to the thymic development of Treg cells, by shaping 
the number of Treg cells and the levels of FOXP3, IL-2 also functions in 
maintaining Treg cells in peripheral compartments. IL-2 signalling activates 
mitogen-activated protein kinase (MAPK), phosphoinositide-3 kinase (PI3K) 
and signal transducer and activator of transcription (STAT) 5 pathway in 
conventional T cells, whereas STAT5 activation is the main outcome of IL-2R 
signalling in Treg cells [130-133]. A patient with a homozygous missense 
mutation in the stat5b gene has also been identified with immune 
dysregulation and impaired expression of FOXP3 and Treg cell function [134], 
implicating STAT5 activation with human Treg cell production. ChiP analysis 
shows that STAT5 binds to the FOXP3 promoter [135] and the untranslated 
region (UTR) of the foxp3 gene in CD25+ cells [123].  
 
1.4.2.4 The role of other T helper cell subsets 
Several GATA-3 binding sites within the FOXP3 promoter negatively regulate 
FOXP3 expression [136]. IL-4-induced GATA-3 repressed FOXP3 expression 
directly by binding to the FOXP3 promoter region. A palindromic GATA-site is 
located 303 bp upstream of the transcription start site (TSS) in the FOXP3 
promoter [122]. Site-specific mutation of this site increased the activity of the 
promoter constructs, thus revealing the repressive nature of this GATA 
element. Keeping GATA-3 expression at low levels might be required to 
induce efficient FOXP3+ iTreg cell generation. 
 
Whether Th1-inducing cytokines (e.g. IL-12, IFN-γ and IL-27) regulate FOXP3 
expression has not been fully investigated. IFN-γ has been shown to be 
required for FOXP3 expression and thus, for conversion of CD4+ T cells into 
Treg cells during EAE [137]. IL-27, which was initially described to control 
development and activation of Th1 cells, also exerts anti-inflammatory 
functions in vivo and has emerged as an immunoregulatory cytokine [138-
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141]. IL-27 is a heterodimeric cytokine, which consists of p28 and EBI3 
subunits. The p28 chain is related to IL-12p35 and has a classical cytokine 
structure, whereas the EBI3 is related to IL12p40 and structurally resembles 
the soluble IL-6R [4,142]. IL-27 is expressed predominantly by APCs and the 
production of both subunits can be induced by toll-like receptor ligands such 
as lipopolysaccharide (LPS), polyriboinosinic:polyribocytidylic acid (Poly I:C) 
and by intact Escherichia coli [4,143,144]. Additionally, signalling via CD40L 
and IL-1β can up-regulate the EBI3 subunit, whereas p28 has been shown to 
be up-regulated by IFN-γ [144,145]. IL-27 is a pleiotropic cytokine with 
contrasting effects, as it also promotes early commitment of naïve T cells to 
the Th1 cell lineage [5,146] and was recently shown to directly antagonize the 
development of Th17-cell responses and to limit IL-17-cell-driven inflammation 
in the central nervous system [140,147]. IL-27 also limits Th17-cell-mediated 
uveitis and scleritis and was suggested to contribute to immune privilege 
[142]. Another key function of IL-27 might be to regulate early inflammatory 
events during acute infections, as IL-27 neutralization protects mice against 
lethal septic peritonitis by enhancing the influx and oxidative-burst capacity of 
neutrophils [148].  
1.4.2.5 The role of STAT molecules  
One mechanism by which cytokines elicit biological responses is through the 
activation of STAT signalling pathways. Similar to the STAT-mediated 
regulation of the specific lineage transcription factor T-bet, GATA-3 and 
RORC2, several studies reported a role for STAT molecules on the foxp3 
gene regulation. IL-2-activated STAT5 can bind to the distal part of the 
FOXP3 promoter [135] as well as to the UTR of the foxp3 gene in CD4+CD25+ 
cells [123], which positively regulate its expression. STAT3 and STAT5 
binding sites have also been found in the exons of the foxp3 gene [149] and 
STAT3 small interfering RNA (siRNA) decreases the FOXP3 protein 
expression [150], indicating a positive regulation of FOXP3 by STAT3. It has 
been shown that the STAT1 activating cytokine IFN-γ is required for FOXP3 
expression and for conversion of CD4+CD25- T cells into Treg cells. 
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Furthermore, impairment of the generation of Treg cells was reported in 
STAT1-/- mice, demonstrating that STAT1 is implicated in the generation of 
CD4+CD25+ Treg cells [151]. Thus, STAT molecules play a crucial role in the 
regulation of FOXP3 expression. 
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Conclusion and aim of the study 
The aim of this study was to gain understanding of the regulation of FOXP3, 
particularly by Th1-inducing cytokines at the promoter level. We identified a 
new pathway regulating FOXP3 expression. This finding provides a valuable 
tool for the elaboration of therapy aiming at the regulation of FOXP3 
expression.  
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Material and Methods 
2.1 T cell population isolation 
 
Peripheral blood mononuclear cells (PBMC) were isolated from Buffy coats of 
healthy donors by Ficoll (Biochrom KG) density gradient centrifugation. CD4+ 
T cells were purified with anti CD4-Dynal magnetic beads and Detach-a-Bead 
antibodies (Dynal) according to the manufacturer’s instructions. 
CD4+CD45RA+ cells were purified by MACS (Miltenyi). CD4+CD45RA+ T cell 
purity was consistently ≥90% as determined by FACS analysis. 
2.2 In vitro T cell differentiation 
 
All T cells were maintained in AIM-V serum free medium (Gibco) with 30 ng/ml 
IL-2 (Peprotech) and polyclonally stimulated with soluble anti-CD3 (2.5 µg/ml; 
clone Okt3; IgG1) and anti-CD28 (2.5 µg/ml; clone B7G5). Naïve T cells were 
driven into neutral condition: 5 µg/ml anti-IL-4, 5 µg/ml anti-IL-12 and 1 µg/ml 
anti-IFN-γ, into Th1 condition: 5 µg/ml anti-IL-4 and 25 ng/ml IL-12 or into 
iTreg condition: 5 µg/ml anti-IL-4, 5 µg/ml anti-IL-12, 1 µg/ml anti-IFN-γ and 5 
ng/ml TGF-β (R&D systems). Proliferating cells were expanded in medium 
containing IL-2 (30 ng/ml). For stimulation of iTreg cells with Th1 cytokines, IL-
27 was used at 60 ng/ml, IFN-γ at 500 U/ml and IL-12 at 25 ng/ml. 
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2.3 RNA isolation and cDNA synthesis 
 
RNA was isolated using the RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s protocol. Reverse transcription of human samples was 
performed with Fermentas reverse transcription reagents (Fermentas) with 
random hexamers according to the manufacturer’s protocol.  
2.4 Quantitative real-time PCR 
 
The PCR primers detecting FOXP3 and T-bet were designed based on the 
sequences reported in GenBank with the Primer Express software version 1.2 
(Applied Biosystems), as listed in Table 1. The PCR primers and probes 
detecting IL-12 p35, IL-12p28 and EBI3 were purchased from Applied 
Biosystems. The prepared cDNAs were amplified using SYBR-PCR 
Mastermix (Applied Biosystems), according to the recommendations of the 
manufacturer in an ABI PRISM 7000 Sequence Detection System (Applied 
Biosystems). Relative quantification and calculation of the range of confidence 
were performed using the comparative ΔΔCT method, as described [125,139]. 
All amplifications were conducted in triplicates. 
 
Primers Sequence 
FOXP3 sense  GAAACAGCACATTCCCAGAGTTC 
FOXP3 antisense  ATGGCCCAGCGGATGAG 
T-bet sense GATGCGCCAGGAAGTTTCAT 
T-bet antisense GCACAATCATCTGGGTCACATT 
Elongation Factor 1a sense  CTGAACCATCCAGGCCAAAT 
Elongation Factor 1a antisense  GCCGTGTGGCAATCCAAT 
Table 1 Primers for Real Time PCR 
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2.5 Flow cytometry 
Cells were stained with the mAb CD25 (Beckman Coulter) prior the FOXP3 
intracellular staining which was performed according to the manufacturer's 
protocol using AlexaFluor®488 anti-human FOXP3 Flow kit clone (295D; 
Biolegend).  
 
Intracellular cytokine labelling was performed with R-phycoerythrin-conjugated 
mouse anti human IFN-γ monoclonal antibody (clone B27; BD Biosciences). 
Cells were stimulated with PMA (25 ng/ml), ionomycin (1 mg/ml), and 
Brefeldin A (10 mg/ml) (Sigma-Aldrich) 5 h prior to staining. Cells were fixed 
and permeabilized using BD cytofix/cytoperm TM kit (BD Biosciences) 
according to the manufacturer's instructions. Matched isotype controls were 
used at the same protein concentration as the respective antibodies.  
 
Treg marker surface staining was performed using fluorescein isothiocyanate-
conjugated mouse anti-PD1 antibody (eBioscience) and mouse anti-
GITR/TNFRSF18 (R&D systems), R-phycoerythrin-conjugated mouse anti 
CTLA-4 (CD152) antibody (BD Pharmingen) and mouse anti-CD-103 antibody 
(Dako). Matched isotype controls were used at the same protein concentration 
as the respective antibodies. 
 
Cell analysis by flow cytometry was performed using a Four-color FACS 
EPICSTM XL-MCL (Beckman Coulter) using the software ExpoTM32 version for 
data acquisition and evaluation. 
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2.6 Cytokine quantification 
 
Supernatants of in vitro differentiated cells that were restimulated at day 12 
with anti-CD3 (2.5 µg/ml) and anti-CD28 (2.5 µg/ml) were analyzed for 
cytokines using Bio-Plex200 System according to the manufacturer's 
protocol (BioRad). 
2.7 Suppression assay 
 
CD4+CD45RA+ T cells were cultured into iTreg condition during 10 days. At 
that point, autologous PBMC and CD4+T cells were isolated. CD4+ responder 
T cells were washed twice with PBS and labeled in PBS 2 µM CFSE 
(Molecular Probes Invitrogen) for 3 min at RT. Cells were washed twice with 
complete RPMI (Life Technologies). Cells were cultured in 96 round-bottom 
plates with anti-CD3 (2.5 µg) during 5 days. The proliferation of CD4+ 




Transcription factor binding sites were identified using TESS software 
(<www.cbil.upenn.edu/cgi-bin/tess/tess33>), which uses matrices of the 
Transfac database. 
2.9 Western blotting 
 
Nuclear Extraction was performed as follows: All buffers contained EDTA-free 
complete protease inhibitor (RocheDiagnostics). Cells were resuspended in 
400 µl buffer A (10 mM KCl, 1 mM DTT, 10 mM Hepes pH 7.9, 1 mM EDTA). 
After 15 min of incubation, 25 µl of 10% Nonidet P-40 (Sigma-Aldrich) was 
added and the tube was vortexed vigorously for 30 sec followed by a 
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centrifugation step (1 min, maximum speed, 4 °C). The translucent nuclear 
pellet was washed once with 1 ml of buffer A, resuspended in 50 µl of buffer B 
(400 mM NaCl, 1 mM DTT, 20 mM Hepes pH 7.9, 1 mM EDTA), and 
incubated for 15 min at 4 °C on a roller. Nuclear debris and genomic DNA 
were removed by centrifugation (5 min, maximum speed, 4 °C). The 
supernatant was diluted 1/3 with buffer D (20 mM Hepes pH 7.9, 1.5 mM 
MgCl2, 0.2 mM EDTA, 1 mM DTT, 0.1 % Nonidet P-40). Total protein 
concentration was determined by a colorimetric protein assay (BioRad). 
Samples were loaded next to a protein-mass ladder (Magicmark; Invitrogen 
Life Technologies) on a NuPAGE 4–12% bis-Tris gel (Invitrogen Life 
Technologies). The proteins were electroblotted onto a polyvinylidene 
difluoride membrane (Amersham Biosciences). Unspecific binding was 
blocked with TBS-tween 3% milk. After blocking, the membranes were 
incubated with the primary Ab in blocking buffer overnight at 4 °C. The blots 
were developed using the proper secondary HRP-labeled Ab and visualized 
with a LAS 1000 camera (Fuji). To confirm sample loading and transfer, 
membranes were incubated in stripping buffer and re-blocked for 1 h and then 
reprobed using anti-GAPDH (6C5, Ambion Ltd.). STAT1 P-Tyr701, STAT3 P-
Tyr705, STAT4 P-Tyr693, STAT5 P-Tyr694 rabbit antibodies and anti-rabbit 
HRP labeled antibodies (Cell Signaling), polyclonal goat anti-FOXP3 (Abcam) 
and anti-goat HRP labeled antibody (Santa Cruz).  
2.10 Amplification of FOXP3 promoter fragments 
 
FOXP3 promoter fragments were amplified by conventional PCR using the 
biotinylated reverse primer 5’-bio-ACCTTACCTGGCTGGAATCACG-3’ 
situated 177 bp downstream of the TSS. Multiple forward primers were 
designed to generate FOXP3 promoter fragments of different length (Table 2). 
Reactions were conducted in 75 mM Tris HCl pH 8.8, 20 mM (NH4)2SO4, 
2 mM MgCl2, 0.2 mM dNTP’s, 0.2 µM of each primer, 6 µg/ml template DNA 
(FOXP3 promoter in pGL3) and 1.25 U of recombinant Taq DNA polymerase 
(Fermentas). The same PCR conditions were used for the amplification of all 
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the products: Initial denaturation step (2 min, 94 °C), 42 cycles of 94 °C for 
30 s, 56 °C for 30 s, 72 °C for 60 s, final elongation step (7 min, 72 °C). PCR 
products were purified by ethanol precipitation: 1/10 volume of 3 M sodium 
acetate and 3 volumes of 100 % ethanol was added to the PCR products, 
mixed and frozen for 1 h at -80 °C and DNA was collected by a centrifugation 
step (30 min, maximum speed, 4 °C). The supernatant was removed and 
residual ethanol was allowed to evaporate. The pellet was eluted in blocking 
buffer (PBS, 0.1 % BSA, 0.05 % Tween20). Quantification of the FOXP3 
promoter probe was done with MassRuler DNA Ladder Mix (Fermentas, 





FOXP3 promoter -1/+177 sense  AAGCCAGGCTGATCCTTTTCTGT 
FOXP3 promoter -59/+177 sense  CGTGGTTTTTCTTCTCGGTA 
FOXP3 promoter -210/+177 sense  AGTCTCATAATCAAGAAAAGG 
FOXP3 promoter -314/+177 sense  TCTCATTGATACCTCTCACCT 
FOXP3 promoter -365/+177 sense  AACTCTATACACTTTTGTTTTAAA 
FOXP3 promoter -420/+177 sense  CTCGGGTTGGCCCTGTGATT 
FOXP3 promoter antisense  ACCTTACCTGGCTGGAATCACG 
Table 2 Primer for amplification of FOXP3 promoter constructs 
 
2.11 FOXP3 promoter ELISA 
 
Nuclear extraction was performed as follow. The cells were pelleted and 
resuspended in buffer C (20 mM HEPES (pH 7.9), 420 mM NaCl, 1.5 mM 
MgCl2, 0.2 mM EDTA, 1 mM DTT, protease inhibitors (Roche Diagnostics), 
and 0.1% Nonidet P-40), and lysed on ice for 15 min. Insoluble material was 
removed by centrifugation. The supernatant was diluted 1/3 with buffer D (as 
buffer C, but without NaCl). 384 well plates, precoated with streptavidin 
(Pierce) were washed 3 times with washing buffer (PBS, 0.05 % Tween20). 
Biotinylated FOXP3 promoter/oligonucleotides probes were added (1 pmol per 
well; 50 fmol/µl) and incubated for 1 h at RT. After 3 washing steps with 
washing buffer, nuclear extract was added (concentration > 0.2 µg/µl) and 
Material and Methods 
 34 
incubated overnight at 4 °C. The lysates were incubated with 10 µg of 
poly(deoxyinosinic-deoxycytidylic acid) (Sigma-Aldrich). The plate was 
washed 3 times with buffer C/D and primary antibody (rabbit anti-STAT1, 
1:200 in buffer C/D, Cell Signaling) was added and incubated at 4 °C for 2 h.  
After 3 washing steps with buffer C/D, secondary antibody (anti-rabbit IgG-
HRP, 1:3000 in buffer C/D, Cell Signaling) was added and the plate was 
incubated for 1 h at 4 °C. The wells were washed 4 times with buffer C/D 
before adding substrate reagent (R&D system). The colorimetric reaction was 
stopped after 2 to 10 min by adding 2M H2SO4. Absorbance at 450 nm was 




2.12 Pull Down 
CD4+ T cells were stimulated with IL-27 (160 ng/ml) and anti-CD3 and anti-
CD28 (2.5 µg/ml) during 1 h at 37 °C. Cells were lysed by sonication in HKMG 
buffer (10 mM Hepes, pH 7.9, 100 mM KCl, 5 mM MgCl2, 10% glycerol, 1 mM 
DTT, 0.5% Nonidet P-40) containing protease inhibitor cocktail (Roche 
Diagnostic). Cells lysate was precleared streptavidin-agarose beads for 1 h 
Figure 9: Schema depicting the steps for the Pull Down ELISA 
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(Amersham Biosciences), then incubated with biotinylated double-stranded 
oligonucleotides (Table 3) and poly (deoxyinosinic-deoxycytidylic acid) 
(Sigma-Aldrich) for 4 h at 4 °C. DNA-bound proteins were collected with 
streptavidin-agarose beads for 1 h. The beads were washed 3 times with 
buffer HKMG and resuspended in NuPAGE loading buffer (Invitrogen Life 
Technologies), heated to 55 °C for 15 min, and the eluants were separated on 
a SDS-polyacrylamide gel and identified by Western Blotting.  




FOXP3 promoter region (-381/-351) WT GTTTTTTTTTTTTTCAAACTCTATACACTT  
FOXP3 promoter region (-381/-351) M GTTTTTTTTGGTTTCACACTCTATACACTT 
FOXP3 promoter region (-361/-331) WT CTATACACTTTTGTTTTAAAAACTGTGGTT 
FOXP3 promoter region (-361/-331) M CTATACACTTTGGTGTTCAACACTGTGGTT 
FOXP3 promoter region (-111/-81) WT AAAAAATTTGGATTATTAGAAGAGAGAGGT 
FOXP3 promoter region (-111/-81) M AAAAAATTTGGATGATTAGCAGAGAGAGGT 
FOXP3 promoter region (-21/+11) WT TGATACGTGACAGTTTCCCACAAGCCAGGC 
FOXP3 promoter region (-21/+11) M TGATACGTGACAGTTGCCCACAAGCCAGGC 
STAT consensus sequence WT CATGTTATGCATATTCCGAGAAGTG 
STAT consensus sequence M CATGTTATGCATATGCCGACAAGTG 
Table 3 Oligonucleotides for pull down analysis 
 
2.13 Chromatin immunoprecipitation (ChIP) assay 
 
ChIP assay was performed using ChIP assay kit following the 
recommendations of the supplier (Upstate Biotechnology). For precipitation, 3 
µg of Ab against STAT1 (M-22), STAT3 (H-190), STAT4 (H-119), STAT5 (H-
134) (Santa Cruz) or anti-acetyl histone H4 (Upstate Biotechnology) were 
used along with a normal rabbit IgG control (Santa Cruz). Primers addressing 
the FOXP3 promoter region are listed in Table 4. The conventional PCR 
products were visualized using an ethidium bromide gel. The real-time PCR 
data were analyzed in relation to the input DNA using the following 
expression: E ([DNAInput]-[DNAIP]). 
 
Primers Sequence 
RT-PCR FOXP3 promoter region (-501/-416) sense CACATAGAGCTTCAGATTCTCTTTCTTT 
RT-PCR FOXP3 promoter region (-501/-416) antisense CCGAGGCAGGCAGAGACA 
RT-PCR FOXP3 promoter region (-204/-114) sense ATAATCAAGAAAAGGAGAAACACAGAGA 
RT-PCR FOXP3 promoter region (-204/-114) antisense TGAGTGTGTGCGCTGATAATCA 
RT-PCR FOXP3 promoter region (-86/+3) sense AGAGGTCTGCGGCTTCCA 
RT-PCR FOXP3 promoter region (-86/+3) antisense GGAAACTGTCACGTATCAAAAACAA 
Table 4 Primers for ChIP analysis 
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2.14 Transfections and reporter gene assays 
 
T cells were pre-activated in complete RPMI (Life Technologies) containing 
rhIL-2 (30 ng/ml) and PHA (2 µg/ml) overnight. For the co-transfection, an 
amount of 3 µg of the pGL3-FOXP3 promoter luciferase reporter vector and 2 
µg of the STAT-pCMV-XL4 was added to 6-10 x106 CD4+ T cells resuspended 
in 100 µl of NucleofectorTM solution (Amaxa Biosystems) and electroporated 
using the T-23 program of the NucleofectorTM. For the single transfection, 5 µg 
of the pGL3-Basic/FOXP3 promoter luciferase reporter vector were used. 
After a 12 h culture in serum-free conditions and stimulation as indicated in 
the figures, luciferase activity in cell lysates was measured by the dual 
luciferase assay system (Promega Biotech) according to the manufacturer’s 
instructions in a Berthold Lumat LB 9507 luminometer.  
 
2.15 Cloning of the FOXP3 promoter, and construction of 
mutant constructs 
 
The human FOXP3 promoter was cloned into the pGL3 vector (Promega 
Biotech) to generate the pGL3 FOXP3 -511/+177 as previously described 
[125]. Site-directed mutagenesis in the FOXP3 promoter region was 
introduced using the QuickChange kit (Stratagene), according to the 
manufacturer’s instructions. The constructs were generated by using pGL3 -
511/+177 as template. Primers used to generate the individual constructs are 
listed in Table 5.  
 
Primers Sequences 
FOXP3 promoter site -99 sense GAAAAAAATTTGGATTATTAGCAGAGAGAGGTCTGCGGCTTC 
FOXP3 promoter site -99 antisense GAAGCCGCAGACCTCTCTCTGCTAATAATCCAAATTTTTTTC 
FOXP3 promoter site -7 sense GATACGTGACAGTGTCCCACAAGCCAG 
FOXP3 promoter site -7 antisense CTGGCTTGTGGGACACTGTCACGTATC 
FOXP3 promoter site UR sense TTGTTTTAAAAACTGTGGTTTCTCGAGAGCCCTATTATCTCATTGATACC 
FOXP3 promoter site UR antisense GGTATCAATGAGATAATAGGGCTCTCGAGAAACCACAGTTTTTAAAACAA 
Table 5 Primers for Mutagenesis 
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2.16 Statistical analysis 
 
The non-parametric Wilcoxon matched paired test and linear regression were 
used to test statistical significance using the GraphPad Prism software 




2.1 The FOXP3 expression is regulated by Th1 cytokines  
The WSX-I/TCCR subunit, which is exclusive to the IL-27 receptor, is 
expressed on CD4+ naïve T cells (Figure 10A) as well as on natural Treg cells 
[157]. Its high expression on in vitro differentiated iTreg cells (Figure 10B) 
suggests that IL-27, which can directly act on naïve cells, regulates Treg cells 
differentiation or function.  
 
To elucidate whether IL-27 has a role during iTreg cell differentiation, we 
cultured human naïve CD4+ T cells under conditions leading to the 
differentiation of iTreg cells (with TGF-β) ± IL-27. Even though TGF-β 
stimulation resulted in elevated FOXP3 mRNA after 3 days (54.1±11.8 fold) 
and protein after 5 days (33.4±6.4%), IL-27 further significantly increased this 
induction (mRNA=98.2±19.9 fold, protein=44.1±6.5%, p=0.0244) (Figure 11). 
To determine whether IL-27 was the only Th1-inducing cytokine influencing 
the FOXP3 expression in the presence of TGF-β, we also cultured naïve CD4+ 
T cells under iTreg condition in the presence of IL-12 or IFN-γ. TGF-β-induced 
FOXP3 expression level was maintained in the presence of IL-12 
(mRNA=56.1±28.9 fold and protein=29.6±6.7%), whereas IFN-γ acted like IL-
27, as an amplifier of TGF-β-induced response (mRNA=97.3±36.7 fold and 
protein=47.7±8.2%, p=0.0312)  (Figure 11).  
 
 
Figure 10: The WSX-1/TCCR subunit is highly expressed on iTreg cells.  
 
FACS analysis of WSX-1/TCCR expression on CFSE labeled A) ex vivo CD4+CD45RA+ T 










Figure 11: IL-27 and IFN-γ  increase TGF-β-induced FOXP3 expression  
 
Human CD4+CD45RA+ T cells were activated with soluble anti-CD3/CD28 and 
differentiated in neutral or iTreg driven condition ± IL-27, IL-12 or IFN-γ as indicated. Cells 
were harvested and FOXP3 expression was analyzed by real-time PCR after A) 24 to 72 h 
or only B) 3 days and C) by FACS analysis, together with CD25 expression, after 5 days. 
Symbols represent A) the mean ± s.e.m. of 6-8 independent experiments, or B) different 





2.2 The cytokine profile of iTreg cells is modified by Th1 
cytokines  
 
To further characterize the cell population developing in the presence of Th1-
inducing cytokines and TGF-β, we performed IFN-γ intracellular staining ( 
Figure 12). Consistent with previous findings [3,158], the frequency of IFN-γ-
producing cells increased upon treatment with IL-27, IL-12 or IFN-γ (23.4±5.1 
vs 36.6±10.2, 56.1±4.7 and 40.3±9.8 % respectively). IFN-γ production was 
low in the presence of TGF-β (11.5±4.5%), whereas IL-12-induced IFN-γ 
production was sustained (49.9±12.4%). The analysis of the supernatants of 
the above cell cultures by Bio-Plex cytokine bead assay confirmed high 
amount of IFN-γ production upon culture with IL-12 and TGF-β (Figure 13). 
TGF-β-mediated suppression of the IFN-γ production was unchanged by IFN-γ 
or IL-27 and IL-4, IL-10 and IL-17 were merely detectable under all conditions 
(Figure 13). Taken together, those findings are ruling out a differentiation into 

















Figure 12: TGF-β  impairs  IFN-γ  inducing capcity of IL-27 and IFN-γ 
 
Human CD4+CD45RA+ T cells were activated with soluble anti-CD3/CD28 and 
differentiated in neutral or iTreg driven condition ± IL-27, IL-12 or IFN-γ as indicated. After 
12 days, intracellular IFN-γ expression was analyzed by FACS following PMA/ionomycin 













Figure 13: The cytokine profile of iTreg cells in the presence of Th1 cytokines 
 
Human CD4+CD45RA+ T cells were activated with soluble anti-CD3/CD28 and 
differentiated in neutral (white bars) or iTreg (black bars) driven condition ± IL-27, IL-12 or 
IFN-γ as indicated. After 12 days, cells were restimulated for 48 h with anti-CD3/CD28 and 
cytokine expression was analyzed by Bio-Plex beads assay. Bars show the mean ± 
s.e.m. of 3 independent experiments. 
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2.3 The suppressive capacity of iTreg is sustained with Th1 
cytokines  
To investigate whether the increased expression of FOXP3 resulted in the 
acquisition of suppressive capacity, we tested the in vitro differentiated iTreg 
cells for their capability to suppress the proliferation of autologous CD4+ 
responder T cells. All in vitro differentiated iTreg cells exhibited suppressive 
ability in a dilution-dependent manner (Figure 14). In contrast to natural Treg 
cells that are anergic, iTreg cells possess the capacity to proliferate upon 
stimulation. To investigate the effect of this proliferation in suppression 
assays, we included stimulated total CD4+ T cells as a control (Figure 14B). 
These cells were stimulated with anti-CD3, anti-CD28 and IL-2 in parallel to 
the in vitro differentiation of iTreg, and used as suppressors in the 
suppression assay. The iTreg-mediated suppression of the proliferation of 
CD4+ responder T cells was higher than the one observed with stimulated 
total CD4+ T cells. Taken together, these findings suggest the induction of 










Recently, the EBI3-IL-12p35 heterodimeric complex, designated as IL-35, was 
shown to be constitutively produced by mouse Treg cells [79] and to be 
required for their suppressive activity. To confirm the regulatory phenotype of 
our iTreg cells, we analyzed the expression of both IL-35 subunits (Figure 15). 
IL-12p35 and EBI3 were both detectable in in vitro differentiated iTreg at 
higher level than in ex vivo CD4+ naïve T cells (Day 0).  
 
 
Figure 14: Suppressive capacity of iTreg cells cultured with Th1-inducing cytokines. 
 
Human CD4+CD45RA+ T cells were in vitro differentiated towards iTreg cells ± IL-27, IL-12 or 
IFN-γ. After 10 days of culture, iTreg cells were activated with soluble anti-CD3, autologous 
irradiated PBMC and CFSE-labeled CD4+ responder T cells in different ratios as indicated. 
The proliferation of CD4+ responder T cells is depicted in A). Data are representative of 4 
independent experiments. B) Percentage of the maximal proliferation. Stimulated CD4+ 














To further investigate the phenotype of the cells cultured in the presence of IL-
27 and TGF-β, we assessed the expression of distinctive Treg markers [86-
88,159]. Because in vitro activated cells express high levels of CD25 
independently of their subset, CD25 expression was not assessed. The 
comparable expression level of CD103, CTLA-4 (CD152), PD-1 and GITR, 
following iTreg or iTreg+IL-27 cell differentiation confirmed the regulatory 
phenotype of Th1 cytokines treated iTreg cells (Figure 16). Taken together, 
these findings suggest an induction of functional iTreg cells in the presence of 
TGF-β and IFN-γ or IL-27. 
 
 
Figure 15: iTreg cells can produce IL-35  
Human CD4+CD45RA+ T cells were in vitro differentiated towards iTreg cells ± IL-
27, IL-12 or IFN-γ. Quantitative RT-PCR of IL-12 p35 and EBI3 of iTreg cells 10 











Figure 16: Treg markers characterization 
Human CD4+CD45RA+ T cells were activated with anti-CD3/28 or in vitro differentiated 
towards iTreg cells ± IL-27. FACS analysis of distinctive Treg markers were performed 




2.3 The indirect influence of IFN-γ  
 
To further investigate the contribution of IFN-γ and IL-27 on the induction of 
FOXP3, we titrated both cytokines and analyzed FOXP3 expression. While a 
concentration-dependent effect was observed for IL-27, IFN-γ did not modify 
the percentage of FOXP3 positive cells at any concentration (Figure 17A-B). 
To further examine the role of IFN-γ, we stimulated naïve CD4+ T cells ± anti-
IFN-γ. FOXP3 mRNA and protein levels were comparable with or without 











Figure 17: The influence of IFN-γ on FOXP3 expression is indirect 
Human CD4+CD45RA+ T cells were in vitro differentiated with or without TGF-β ± 
increasing concentration of A) IL-27 (0, 20, 80 and 160 ng/ml) and B) IFN-γ.(0, 250, 500 
and 1000 U/ml) and analysed by FACS for FOXP3 positive cells.  
Human CD4+CD45RA+ T cells were unstimulated or TGF-β stimulated ± anti-IFN-γ and 
FOXP3 expression was analyzed C) by real time PCR after 3 days and D) by FACS after 5 







Recently, it was demonstrated that IFN-γ-induced STAT1 binds to the IL-27 
promoter and induces IL-27 expression [145]. IL-27, which has been shown to 
be produced by dendritics cells, monocytes and endothelials cells, is also 
expressed by the T cell immortal Jurkat cell line. Both subunits of IL-27 were 
detectable after 48 hours stimulation in the presence of IFN-γ (Figure 18). 
Taken together, these findings suggest that IFN-γ indirectly influences FOXP3 
expression via the production of IL-27 in human T cells.  
 
 Figure 18: IL-27 is induced by IFN-γ 
Quantitative RT-PCR of IL-12 p28 and EBI3 of human CD4+CD45RA+ T cells before and 





2.4 T-bet influences the FOXP3 expression 
 
To investigate the role of the Th1-specific transcription factor T-bet on the 
expression of FOXP3, T-bet expression during the human naïve CD4+ T cell 
differentiation with or without TGF-β ± IL-27, IL-12 or IFN-γ was analyzed. In 
accordance with their role as Th1-inducing cytokines, IL-27, IL-12 and IFN-γ 
induced T-bet mRNA expression in the absence of TGF-β. Even though TGF-
β stimulation resulted in reduced T-bet mRNA levels, Th1 cytokines remained 
capable of inducing T-bet mRNA. Since T-bet was still detectable under iTreg 
culture conditions, we investigated whether its expression correlated with 
FOXP3 expression. In harmony with the potentiation of FOXP3 by Th1 
cytokines, T-bet expression positively correlated with FOXP3 expression (r2= 
0.393, p=0.0004) (Figure 20). However, the weak correlation observed 
suggest the implication of complementary and more direct mechanisms in the 








Figure 19: T-bet is expressed during iTreg cell differentiation  
Human CD4+CD45RA+ T cells were activated with soluble anti-CD3/CD28 and 
differentiated in iTreg driven condition ±  IL-27, IL-12 or IFN-g as indicated. Cells 
were harvested and FOXP3 expression was analyzed by real-time PCR after 24 to 















Figure 20: T-bet expression correlates with FOXP3 expression. 
The real time PCR Ct value of FOXP3 and T-bet were substracted from the Ct 
value of the house keeping gene Elongation factor 1. A linear regression was 
performed. Straight line represent linear regression. Dashed lines represent 
95% confident intervals. Symbols represent different donors.  
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2.5 The FOXP3 promoter contains STAT binding sites  
Several studies reported a potential role of STAT molecules on the foxp3 gene 
regulation [153]. STAT3 and STAT5 binding to FOXP3 promoter, to the 
untranslated region (UTR) and to exons of the foxp3 gene have been reported 
[126,138,152]. TESS analysis of the human FOXP3 promoter predicted 4 
putative STAT binding sites at 373bp, 351bp, 99bp and 7bp upstream of the 
Transcription Start Site (TSS)). Positions of STAT binding sites within the 
FOXP3 promoter/gene are summarized ( 






Figure 21: FOXP3 promoter sequence  
Sequence depicting the STAT binding sites and the position of primers and 




Both IL-27 and IFN-γ are known to induce STAT1 Tyr701 phosphorylation and 
activation. Since the induction of FOXP3 is dependent on TGF-β signalling, 
we analyzed whether IL-27 and IFN-γ-induced STAT1 phosphorylation 
occurred in the presence of TGF-β. Both cytokines induced STAT1 
phosphorylation, which enable its DNA binding, whereas IL-12 unaffected this 
molecule (Figure 22).  
 
Direct binding of STAT1 to the FOXP3 promoter was investigated in a FOXP3 
promoter ELISA analysis. Oligonucleotides corresponding to different lengths 
of the FOXP3 promoter were coated on ELISA plates. STAT1 binding was 
detectable by chemiluminescence following incubation with nuclear extract 
from IL-27-stimulated CD4+ T cells and suitable antibodies and detection 
reagents. STAT1 strongly bound to its specific consensus sequence, but not 
to the mutated sequence, which validated the specificity of the assay. STAT1 
bound the full-length FOXP3 promoter construct (-420/+177) containing all 
STAT binding sites. A similar binding was observed in FOXP3 promoter 
constructs lacking sites at positions -373bp and/or -351bp (-365/+177, -
314/+177, -210/+177), was reduced in the construct lacking the site at position 
-99bp (-59/+177) and was totally abolished in the construct lacking the site at 















Figure 22: Activated STAT1 can bind to FOXP3 promoter 
Primary human CD4+ T cells were stimulated with anti-CD3/28, IL-2, TGF-β ± IL-27, IL-12 
or IFN-γ during 15 and 60 min. The nuclear extract was analyzed by Western blot for 
STAT1 Tyr 701 phosphorylation A). GAPDH was used as an internal loading control. Data 
are representatives of 3 independent experiments. Primary human CD4+ T cells were 
stimulated with anti-CD3/28, IL-2, TGF-β and IL-27 for 30 min and the nuclear extract was 
tested B) for the binding of STAT1 to the consensus sequence or the mutated consensus 
sequence, and to different lengths of the FOXP3 promoter. Bars show the mean ± S.D. of 




 In agreement with the FOXP3 promoter ELISA results (Figure 22), STAT1 
binding was observed to the sites -99bp and -7bp in pull down analysis using 
30 bp probes containing putative STAT binding sites and the surrounding 
regions in the FOXP3 promoter (Figure 23). This suggests that activated 
STAT1 can recognize and bind 2 sequences within the FOXP3 promoter. 
Because IL-27 can also activate other STAT family members, we further 
tested the possibility that other IL-27 activated STAT molecules (e.g. STAT3, 
STAT4 and STAT5) bind the putative STAT binding sites within the FOXP3 
promoter. A slight binding of STAT3 was also observed to the site at position -
7 and even though STAT4 and STAT5 were activated and able to bind the 
STAT consensus sequence following IL-27 stimulation, there was no apparent 
binding to any of the probes (Figure 23 and data not shown). 
 
 
Figure 23: : STAT1 binds to the FOXP3 promoter 
 
Primary human CD4+ T cells were stimulated with anti-CD3/28, IL-2, TGF-β and IL-27 for 
30 min and the nuclear extract was tested for the binding of STAT1 and STAT3 to the 
consensus sequence or the mutated consensus sequence, and to different lengths of the 
FOXP3 promoter. Data are representative of 3 independent experiments. 
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2.6 STAT1 binds the FOXP3 proximal promoter in vivo 
 
To clarify the importance of the STAT molecules’ binding in regulating foxp3 
gene expression in vivo, we performed a ChIP assay. In primary CD4+ naïve T 
cells, only STAT1 binding was clearly detectable to the FOXP3 promoter 
following stimulation with TGF-β, anti-CD3, anti-CD28, IL-2 and IL-27 for 30 
min (Figure 24). The location of STAT1 binding in vivo was evaluated by ChIP 
assay using PCR primers amplifying 3 regions of the FOXP3 promoter (-501/-
416, -204/-114, -86/-3). Coherent with the pull-down analysis (Figure 23), 
STAT1 was binding to the regions in proximity to the sites at positions -99bp 
and -7bp (-214/-114, -83/-3) (Figure 24). Thus, STAT1 was the only STAT 
member binding to sites at positions -99bp and -7bp of the FOXP3 proximal 











Figure 24: STAT1 is the only IL-27-induced STAT member binding the FOXP3 
promoter in vivo 
 
Primary human CD4+ T cells were stimulated with anti-CD3/28, IL-2, TGF-β and IL-27 for 
30 min. Cells were analyzed by ChIP for STAT1, STAT3, STAT4 and STAT5 binding to the 
FOXP3 promoter. The chromatin DNA obtained before (Input) and after 
immunoprecipitation with anti-STAT antibody or with the respective isotype control was 
analyzed by real time PCR with 3 specific primers pairs for the FOXP3 promoter. Bars 




2.7 IL-27-induced STAT1 regulates foxp3 gene expression 
 
Functional significance of STAT1 binding to the FOXP3 promoter was 
analyzed by FOXP3 promoter luciferase assay using IL-27-stimulated CD4+ T 
cells. The strongest luciferase activity was generated with -511/+177 pGL3 
FOXP3 promoter reporter plasmid after co-transfection with STAT1 (p=0.005) 
(Figure 25A), reflecting a role of STAT1 in regulating the FOXP3 promoter 
activity. The respective contribution of the -99bp and -7bp sites in the STAT-
mediated regulation of FOXP3 was examined using mutant constructs. The 
mutations A-92C and T-6G, which abolished the STAT binding capacity, 
greatly decreased the overall activity of the promoter, whereas an unrelated 
mutation (AT-327GA) did not change it (Figure 25B). This underlined the 
importance of these binding sequences in the regulation on the promoter 
activity. IL-27 slightly increased the transactivation of the FOXP3 promoter 
luciferase reporter construct (p=0.0321) (Figure 25C). This effect was no 
longer significant in the mutant constructs, suggesting that IL-27 mediated 














Figure 25: IL-27-induced STAT1 regulates FOXP3 promoter’s activity 
 
Primary CD4+ human T cells were activated with IL-2 and PHA. A) Cells were transfected 
with pGL3 (Basic or FOXP3 -511/+177) and pCMV (empty or STAT1) vectors as indicated 
and stimulated with anti-CD3/28, IL-2, TGF-β and IL-27 18 h prior measurement. Cells 
were transfected an empty vector (pGL3 Basic), a WT FOXP3 promoter containing vector 
or a mutated FOXP3 promoter containing vector and stimulated with B) anti-CD3/28, IL-2, 
TGF-β and IL-27 or C) anti-CD3/28, IL-2, TGF-β ± IL-27 during 18 h prior measurement for 
the relative luciferase light units. Unstimulated basic vector is set as 1. Bars show mean ± 




2.8 IL-27 controls foxp3 gene expression at the epigenetic 
level 
STAT1 has been shown to be implicated in chromatin remodeling following 
IFN-γ stimulation [160]. A single point mutation that prevented its 
phosphorylation was sufficient to abolish the chromatin remodeling. The role 
of IL-27 in histone modification of the FOXP3 promoter was investigated by 
performing ChIP assays with anti-acetyl histone H4 (Figure 27). In iTreg cells 
(cultured for 8 days) histone H4 molecule was acetylated in the -501/-416 
region of the FOXP3 promoter (Figure 27). Addition of IL-27 in the culture 
induced histone H4 acetylation in the regions near STAT1-binding sequences 
(-204/-144, -86/-3). This indicated a role of IL-27-induced STAT1 in regulating 











Figure 27: IL-27-induced STAT1 regulates histone acetylation 
 
Human CD4+CD45RA+ T cells were activated with soluble anti-CD3/CD28 and 
differentiated in iTreg driven condition without or with IL-27. After 8 days, cells were 
analyzed by ChIP for histone H4 acetylation in the FOXP3 promoter. The chromatin DNA 
obtained before (Input) and after immunoprecipitation with anti-acetyl H4 antibody or with 
the isotype control was analyzed by real-time PCR with 3 specific primers pairs for the 




Collectively, these findings suggest that IL-27 has the capability to act on 
naïve CD4+ T cells during their differentiation into effector cells. When IL-27 
stimulation is coupled with TGF-β stimulation, cells undergo iTreg 
differentiation with reduced IFN-γ production and potently suppressive 
capacity. Part of the mechanism leading to this differentiation is mediated via 
the induction of FOXP3. Phosphorylation of STAT1 Tyr701 following IL-27 
stimulation enables its binding to the sites at positions -99bp and -7bp of the 
FOXP3 promoter, which increases the expression of the foxp3 gene via 
epigenetic regulation of the promoter.  
 
2.9 Statement of contribution for publications 
 
I have performed all the experiments for the thesis. I used the FOXP3 
promoter into the pGL3 vector that has been previously cloned by Pierre-Yves 







By acting directly on chromatin remodeling [156], the transcriptional regulator 
FOXP3 plays an important role in the early differentiation process of iTreg 
cells. This thesis revealed a mechanism of FOXP3 expression regulation by 
Th1 cytokines. In a first step, the influence of Th1 cytokines on iTreg 
generation was analyzed and led to the finding that IFN-γ and IL-27 further 
enhance TGF-β-mediated induction of FOXP3. In a second step, the 
molecular mechanism of the FOXP3 induction was investigated and led to the 
discovery that following IL-27 costimulation with TGF-β, STAT1 is activated, 
binds the FOXP3 proximal promoter and permissively modifies the histone 





3.1 IL-27 is more than a Th1-inducing cytokine 
 
The cytokine microenvironnement during the priming of naïve CD4+ T cell by 
APC dictate their differentiation. IL-12, which is produced following type 1 
pathogen infection, has been recognized as Th1-inducing cytokine. IL-27 and 
IFN-γ are necessary, but functionally redundant, for the T-bet and IL-12Rβ2 
expression, which increases the IL-12 responsiveness of the naïve cells. 
However, IL-27 seems to act as a sensor of the current immune state and its 
effects are flexible according to the type and the amount of cytokines in the 
milieu. In 3 different inflammatory conditions, IL-27 was observed to act as 
such sensor. During Toxoplasma gondii infection, high levels of IL-12 are 
present and large amount of IFN-γ are produced. Under this condition, IL-27 
does not further enhance Th1 development [149]. However, during a 
Leishmania major infection, at low level of IL-12, or when IFN-γ is neutralized, 
IL-27 significantly increases IFN-γ production and participates in the Th1 cell 
differentiation [150]. Following Trichuris muris infection, high levels of IL-4 are 
produced and in this case, the main role of IL-27 is to inhibit the expansion 
phase of the Th2 cells, mainly by downregulating GATA-3 expression via T-
bet [4,162]. IL-27Ra–/– mice develop more severe symptoms in EAE [143,150] 
showing the ability of IL-27 to directly suppress Th17 cell differentiation. The 
mechanism by which IL-27 exerts its extensive suppressive effects remains 
unclear. In this thesis, we suggest that IL-27 potentiates the effect of other 
cytokines according to the cytokine microenvironment. We show a function of 
IL-27 in ampliflying the effect of TGF-β on the induction of FOXP3 and thus, in 
potentiating the induction of iTreg cells. In favour of this hypothesis, our pull 
down analysis reveals a weak binding of STAT3 to the FOXP3 promoter. 
STAT1 and STAT3 are known to have opposite function [163] and it was 
recently shown that STAT3 inhibits iTreg development [164]. IL-6 is a major 
activator of STAT3 and acts in concert with TGF-β to induce the expression of 
RORC2, which leads to Th17 cells differentiation [23,24]. Considering the 
close relationship between Th17 and iTreg cells, IL-27 might play a critical 
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role in the lineage decision-making between Th17 and iTreg cells. In the 
presence of TGF-β, IL-27-induced STAT1 might prevent the inhibitory effect of 





3.2 IL-27 increases FOXP3 expression in humans 
 
Costimulation of naïve CD4+ T cells with TGF-β and IL-27 or IFN-γ induces 
higher FOXP3 expression than TGF-β stimulation alone, and generates 
potently suppressive iTreg cells. The specific role of IL-27 on FOXP3 
expression has been recently investigated in mice and, in contrast to our 
findings, revealed that IL-27 inhibits TGF-β-driven induction of FOXP3 and 
iTreg cell differentiation [165,166]. In theses studies, IL-27 was used at lower 
concentrations than in our study, suggesting that the pleiotropic effects of IL-
27 might be concentration dependent. However, the IL-27-mediated induction 
of FOXP3 was observed in a concentration-dependent manner, even with 
lower concentrations. We propose that IL-27 play differential role in murine 
and humans cells. A qualitative species difference for IL-27 has also been 
suggested regarding its role on monocytic cells. Resting murine macrophages 
are minimally responsive to IL-27, but human monocytes are strongly 
activated by IL-27 in a STAT1-dominant manner [167]. Since the function of 
IL-27 was also STAT1-dependent in the current study, it might explain the 
these discrepancies between man and mouse. 
 
The equivalence of FOXP3’s regulation and function between mice and 
human is also a matter of debate. While Foxp3 is exclusive to Treg cell 
lineage in mice, it can be transiently expressed in activated human T cells 
[110,168,169]. However, the FOXP3+ cells acquire suppressor activity after 
prolonged cultures [170] and lentivirus-based ectopic expression of FOXP3 is 
sufficient to generate potent and stable human CD4+ Treg cells [171]. Even 
though the regulation of FOXP3 expression differs between man and rodents, 
its expression in human CD4+ T cells relates to regulatory activity.  
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3.3 IL-27 sustains iTreg differentiation in humans 
 
Since the FOXP3 expression is higher after IFN-γ or IL-27 treatment, we 
anticipated that iTreg cells driven in the presence of those cytokines would 
exhibit higher suppressive capacity. However, the proliferative response of co-
cultured CD4+ responder T cells was similar between all Th1-boosted iTreg 
and regular iTreg cells. Since post-translational modifications of FOXP3 
influence its function in vivo [172], additional factors modifying FOXP3’s 
acetylation or phosphorylation may be required to translate expression 
differences into higher suppressive functionality.   
 
Together with the surface expression of distinctive Treg cell markers, the IL-
27-treated iTreg cells are capable of producing the newly identified Treg 
cytokine IL-35. Even though it the exact function of this cytokine in the human 
system remains to be elucidated, these findings support the regulatory 




3.4 T-bet is a secondary player in the induction of FOXP3 
 
Because naïve CD4+ T cell differentiation is orchestrated by lineage-specific 
factors, we anticipated that the Th1-specific factor T-bet would inhibit the 
differentiation of Treg cell subsets like it was reported concerning Th2 cells 
differentiation. T-bet was shown to repress Th2 lineage commitment through 
tyrosine kinase-mediated interaction with GATA-3, that interferes with the 
binding of GATA-3 to its target DNA [168]. However, the positive correlation 
between T-bet and FOXP3 expression, and the early increase of T-bet 
following cell stimulation, suggest a role for T-bet in inducing FOXP3. GATA-3 
has been shown to inhibit FOXP3 expression via direct interaction to the 
FOXP3 promoter [136]. The tyrosine kinase-mediated interaction between T-
bet and GATA-3 may reduce the GATA-3-mediated inhibition on the foxp3 
gene, and thus favour FOXP3 expression. 
 
In addition to GATA-3’s capacity to induce Th2 cytokine production, it can 
block Th1 cytokine production via down-regulation of STAT4 and indirectly the 
IL-12Rβ2 chain [10]. However, if T-bet is induced at sufficient levels, such 
GATA-3 suppression can be counteracted. This ability of T-bet to oppose the 
action of GATA-3 may be not only essential in permitting Th1 differentiation, 




3.5 IFN-γ  acts in an indirect manner 
 
In addition to IL-27, IFN-γ also potentiates TGF-β-mediated induction of 
FOXP3. Even though the neutralisation of IFN-γ diminished TGF-β-induced 
FOXP3 expression, the induction of FOXP3 was not in a concentration 
dependent manner. This suggests an indirect effect of IFN-γ on FOXP3. 
Furthermore, pull down analysis of STAT1 using IFN-γ stimulated CD4+ T cells 
failed to show any STAT1 binding to the FOXP3 promoter  (data not shown). 
The duration of STAT activation has been associated with the magnitude of 
target gene expression [169-171]. In the presence of TGF-β, we showed that 
tyrosine phosphorylation of STAT1 is sustained for a long time following IL-27 
stimulation, but waned more rapidly with IFN-γ stimulation. The long lasting 
effect of IL-27 on STAT1 phosphorylation can be attributed to the WSX1 
subunit of its receptor. It has been shown to activate STAT1 in other systems 
[172]. The gp130 subunit of the IL-27R functions as a signal transducer and 
as a target for inhibition. Activation of STAT1 by IFN-γ is resistant to inhibition 
by TLR-induced pathways, whereas IL-27 activated STAT1 is susceptible to 
inhibition by factors activating p38. Thus STAT1 is differentially regulated 
following IL-27 or IFN-γ stimulation and only the IL-27-induced STAT1 is 
implicated in FOXP3 induction. Possibly to bypass this impaired STAT1 
function, both IL-27 subunits are induced following IFN-γ treatment. This 
suggests that induction of FOXP3 by IFN-γ is a subsequent effect of IL-27.  
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3.6 IL-27-induced STAT1 regulates foxp3 gene 
expression  
 
It is well established that TGF-β induces FOXP3 expression and can convert 
CD4+CD25- into CD4+CD25+ Treg cells. Until very recently, no molecular 
mechanisms had been proposed to explain the manner by which TGF-β 
mediates FOXP3 induction. It was suggested that TGF-β is mandatory for the 
induction of FOXP3 by keeping a low expression of GATA-3 and T-bet [173-
175]. TGF-β mediates the phosphorylation of intracellular Smad proteins, 
which enables the association of Smad4, Smad2 and Smad3. After 
translocation into the nucleus, Smad complexes bind to Smad binding 
element (SBE) and control gene expression by recruiting coactivators that 
contain HAT activity or corepressors with HDAC activity to activate or repress 
target genes, respectively [176]. Recently, a SBE site was discovered in the 
enhancer region located downstream of the foxp3 gene’s TSS [120]. The 
transcription factors Smad3 and NFAT are required for activity of this Foxp3 
enhancer, and both factors are essential for histone acetylation in the 
enhancer region. This allows the enhancer complex to interact with the 
promoter region and to induce Foxp3 expression. We previously showed that 
the FOXP3 promoter region carries an important regulatory unit for the 
regulation of the foxp3 gene. The FOXP3 human promoter was previously 
localized by 5’-RACE, at -6221 bp upstream from the TSS [122]. The 
sequence upstream of the UTR shows a high degree of conservation between 
human, mouse and rat, which indicates the presence of important regulatory 
elements. In addition to several NFAT and AP-1 binding sites that act as TCR-
responsive units of the foxp3 gene, the FOXP3 promoter contains many 
GATA-3 binding sites that negatively regulate FOXP3 expression. In this 
thesis, we identified 2 functional STAT binding sites. TESS analysis predicted 
4 putative STAT binding sites (TTN5AA) within the region -511/+177 of the 
human FOXP3 promoter (Site 373bp, Site 351bp, Site 99bp and Site 7bp 
upstream the TSS). Consistent with previously demonstrated STAT1-
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mediated effect of IL-27 on naïve T cell differentiation, we show that IL-27 
regulates the induction of the human foxp3 gene through the activation of the 
STAT1 transcription factor. An important role of STAT1 in regulating immune 
response has previously been shown. STAT1-deficient mice expressing a 
transgenic TCR against myelin basic protein have higher susceptibility to EAE 
due to a reduced number as well as a functional impairment of the CD4+ 
CD25+ Treg cells [151]. Even though the determination of Treg cells was 
based only on the CD25 expression and not on FOXP3 expression, the 
adoptive transfer of wild-type Treg cells into STAT1-deficient hosts was 
sufficient to prevent the development of autoimmune disease. This 
demonstrates an essential role of STAT1 in the maintenance of immunological 
self-tolerance. By binding to the proximal part of the promoter, STAT1 directs 








Chromatin opening is an important step in de-repressing silenced genes 
[177,178] and the expression of the foxp3 gene depends on the availability of 
its chromatin [124,179]. Permissive histone modifications of the FOXP3 
promoter, the intronic differentially methylated region 3 and the enhancer at 
position +2079 to +2198 were reported in Treg cells [120,124,179]. The 
histone modifications near the foxp3 TSS were described as a marker of the 
inducibility of Foxp3 and correlate with its expression [180]. STAT1 has been 
described to induce transcription by chromatin remodelling following IFN-γ 
stimulation [155]. In this thesis, we confirm that histone acetylation of this 
region promotes FOXP3 expression and reveal that this mechanism is 
mediated by IL-27-induced STAT1. The late increase of FOXP3 following 
TGF-β stimulation implies the need of numerous intracellular mechanisms to 
regulate its expression. The rapid binding of STAT1 to the FOXP3 promoter 
argues that IL-27-induced STAT1 may regulate early events allowing the 
recruitment and binding of the other regulatory factors (e.g. NFAT, AP-1, Sp-




















Figure 28: Model of FOXP3 regulation by Th1 cytokines 
The upper scheme represents the foxp3 gene regulation by TCR, TGF-βR and IL-2R 
stimulation. The chromatin of the proximal promoter is in a restrictive conformation. The 
bottom scheme depicts the effect of IFN-γ and IL-27 stimulation. IFN-γ might participate 
indirectly on FOXP3 induction via the production of IL-27. Activation of the gp130 subunit of 
the IL-27R has a long lasting activating effect on STAT1, which allows its binding to the 
proximal part of the promoter. This binding increases the accessibility of the chromatin, which 




3.8 Conclusion and Outlook 
By investigating the human FOXP3 promoter we could explain the molecular 
mechanisms involved in FOXP3 up-regulation following costimulation of naïve 
CD4+ cells by TGF-β and IL-27 or IFN-γ. We also described that IL-27-induced 
STAT1 acts as an amplifier of FOXP3 expression that binds directly and 
represses the FOXP3 promoter, which increases the accessibility of the 
chromatin (Figure 28).  
 
Our data suggest a new pathway of regulation for FOXP3 induction with 
permissive epigenetic modification of the proximal promoter by IL-27-induced 
STAT1 molecule. The mechanisms involved in regulating FOXP3 in iTreg 
cells are of considerable interest due to the essential contribution of FOXP3 in 
preventing autoimmune diseases. The results of this thesis not only gives new 
insights into the molecular mechanisms implicated in regulating FOXP3 
expression and iTreg generation, but may also lead to the development of 
therapeutic approaches targeting IL-27 in order to modulate iTreg induction or 
to restore tolerance in many immune-mediated diseases.  
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